Talk:SMT D002

Is there any OBJECTIVE information out there apart from Summit's own reports? As far as I can tell, there has been no independent confirmation of their trial results, the company stock is in the toilet(1), and they are desperately trying to sell the company. Why would the owners be trying to sell a company that purportedly has the cure for acne??

(1) http://www.londonstockexchange.com/en-gb/pricesnews/prices/System/DetailedPrices.htm?ti=SUMM#PriceChart -- stock had been going nowhere but down for the past year! Hence, care required that this article does not become a snake-oil/stock-kiting tool -- Belzecue (talk) 09:43, 30 March 2009 (UTC)

I am increasingly of the opinion that SMT D002 could have been a lot of hype over nothing. The original trial by DanioLabs, which later became Summit, sounds like the one they carried out on Oxybutynin: http://www.sumobrain.com/patents/wipo/Treatment-excess-sebum-production/WO2007141530.html If SMT D002 is Oxybutynin then the experience of people who have used Oxybutynin suggests that it is neither effective for sebum reduction, nor free from significant side effects. I really wonder about the validity of Summit's trial and the way they presented the results. —Preceding unsigned comment added by 59.3.195.71 (talk) 23:45, 11 August 2010 (UTC)